AECOPDAcute Exacerbations of Chronic Obstructive Pulmonary Disease
References in periodicals archive ?
3,4 Antibiotics are usually used for treating AECOPD in clinics; however, not all AECOPD patients require antibiotic therapy.
A prospective observational study of COPD patients who were consecutively admitted due to AECOPD at the Institute for Pulmonary Diseases of Vojvodina, Serbia, between July 2013 and September 2014.
It is also useful to use CRP to identify patients presenting with AECOPD who are most likely to benefit from antibiotics.
This was a single-centre, single-blinded, parallel group trial with adult patients admitted to Middlemore Hospital with an AECOPD with sputum production.
The present study was planned to determine whether NLR and PLR can be used like CRP in AECOPD diagnosis.
A study of 67,651 ED visits for AECOPD found NIV use, compared with invasive mechanical ventilation, was associated with reduced inpatient mortality of 46%, shortened hospital length of stay by 3 days, reduced hospital charges of approximately $35,000 per visit, and modestly reduced risk of iatrogenic pneumothorax.
Infectious agents are recognised as a major pathogenic factor in AECOPD, accounting for an estimated 50-60% of exacerbations (mostly bacterial and viral).
presentation(s) 1725 (1) (2) 1747/04 31,70/bronchial SXTR TETR asthma, AECOPD 15B 1670 (1) (1) 1710/04 48/AECOPD 3 CIPR 1700 (1) (1) 958/04 60/pneumonia 3 TETR 1701 (1) (1) 817/04 81/bronchial asthma 7C PENI SXTR TETR 1702 (1) (1) 1388/04 61/AECOPD 7F SXTR 1759 (1) (1) 500/04 29/pneumonia 7F SXTR TETR 1726 (1) (1) 233/04 60/AECOPD 29 SXTR TETR 289 (2) (1) 1177/04 77/COPD 5 SXTR, TETR 63 (2) (1) 1597/04 50/AECOPD 14 None 1294 (1) 1671/04 50/bronchial asthma 22F CHLR CIPR LFXR 1671 (1) (1) 1592/04 24/tropical 32A SXTR CHLR pulmonary TETR eosinophilia Sequence Identical or related genotypes (SLV) from type isolates recovered from other countries/ ST (no.
In IP, AECOPD patients were with normal serum magnesium level and 23 had hypomagnesaemia.
Some studies report that 3-6% of AECOPD (Acute Exacerbations of COPD) patients require hospitalization and the mortality ranges from 3 to 10% during these admissions.
In this context, the possibility of treating patients with AECOPD with inhaled corticosteroids, having less systemic adverse effects is of particular interest.